★ Analysts see FY2028 revenue reaching $6.2B — +6.5% growth in a single year.
What Could Go Wrong
01Increased competition from low-cost manufacturers in Asia could pressure margins, potentially reducing operating margin by 5% in the next fiscal year.
02Regulatory delays in the approval of new devices could impact revenue growth, with a potential 10% reduction in projected sales.
03Technological disruption from emerging competitors in sleep and respiratory care
"Management noted, 'While we continue to innovate, the competitive landscape is evolving rapidly, which may affect our market position.'"
Moat: ResMed's competitive advantage is supported by its strong brand and proprietary technology…
Watch: The rise of low-cost manufacturers in emerging markets poses a significant threat to ResMed's market share.
growth - Investors are likely attracted to ResMed due to its strong revenue growth and innovative product pipeline.
Low - ResMed's business is not heavily reliant on debt financing, and interest rate changes have minimal impact on its operations.
Watch on earnings: Sleep apnea diagnosis rates, Market share in the sleep and respiratory device segments, Growth in software subscription revenue.
One Sentence Summary:
The bear case: increased competition from low-cost manufacturers in asia could pressure margins, potentially reducing operating margin by 5% in the next fiscal year.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
